We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · September 22, 2022

Switching Adults With Sickle Cell Disease From Full Agonist Opioids to Buprenorphine

American Journal of Hematology


Additional Info

American Journal of Hematology
Converting Adults with Sickle Cell Disease from Full Agonist Opioids to Buprenorphine: A Reliable Method with Safety and Early Evidence of Reduced Acute Care Utilization
Am. J. Hematol 2022 Aug 26;[EPub Ahead of Print], MS David, J Jones, A Lauriello, I Nnake, M Plazas Montana, K Lasko, C Buri-Nagua, Y Olagbaju, E Williams, M Sears, B Salzberg, SM Lanzkron, CP Carroll

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading